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a  b  s  t  r  a  c  t
Serogroup  C  meningococcal  (MenC)  disease  accounts  for  one-third  of  all meningococcal  cases  and  causes
meningococcal  outbreaks  in the  U.S.  Quadrivalent  meningococcal  vaccine  conjugated  to  diphtheria  tox-
oid (MenACYWD)  was  recommended  in  2005  for adolescents  and  high  risk  groups  such  as  military
recruits.  We  evaluated  anti-MenC  antibody  persistence  in U.S.  military  personnel  vaccinated  with  either
MenACYWD or meningococcal  polysaccharide  vaccine  (MPSV4).  Twelve  hundred  subjects  vaccinated
with  MenACYWD from  2006  to 2008  or MPSV4  from  2002  to  2004  were  randomly  selected  from  the
Defense  Medical  Surveillance  System.  Baseline  serologic  responses  to MenC  were  assessed  in all  subjects;
100 subjects  per  vaccine  group  were  tested  during  one  of the following  six  post-vaccination  time-
points:  5–7, 11–13,  17–19,  23–25,  29–31,  or 35–37  months.  Anti-MenC  geometric  mean  titers  (GMT)
were measured  by rabbit  complement  serum  bactericidal  assay  (rSBA)  and  geometric  mean  concen-
trations  (GMC)  by  enzyme-linked  immunosorbent  assay  (ELISA).  Continuous  variables  were  compared
using  the  Wilcoxon  rank  sum  test  and  the proportion  of  subjects  with  an rSBA  titer ≥8  by  chi-square.
Pre-vaccination  rSBA  GMT  was  <8  for the MenACWYD group.  rSBA  GMT  increased  to  703  at  5–7  months
post-vaccination  and  decreased  by  94%  to  43  at 3 years  post-vaccination.  GMT  was  signiﬁcantly  lower  in
the  MenACWYD group  at 5–7 months  post-vaccination  compared  to  the  MPSV4  group.  The  percentage
of  MenACWYD recipients  achieving  an  rSBA titer  of  ≥8  decreased  from  87%  at  5–7 months  to  54% at  3
years.  There  were  no  signiﬁcant  differences  between  vaccine  groups  in the proportion  of  subjects  with  a
titer of  ≥8  at  any  time-point.  GMC  for the  MenACWYD group  was  0.14  g/mL  at  baseline,  1.07  g/mL  at
5–7  months,  and  0.66  g/mL  at 3 years,  and  signiﬁcantly  lower  than  the  MPSV4  group  at all  time-points.
Anti-MenC  responses  wane  following  vaccination  with  MenACYWD; a booster  dose  is  needed  to  maintain
protective  levels  of  circulating
Published  by
Abbreviations: ACIP, Advisory Committee on Immunization Practices; CDC, Centers 
oD,  Department of Defense; DoDSR, Department of Defense Serum Repository; ELISA, e
eometric mean titer; LLQ, lower limit of quantitation; MenACYW, quadrivalent menin
accine conjugated to diphtheria toxoid; MenC, Serogroup C Neisseria meningitidis; MPSV4
enter; rSBA, rabbit complement serum bactericidal assay; VE, vaccine effectiveness.
∗ Corresponding author at: Centers for Disease Control and Prevention, 1600 Clifton Ro
E-mail  address: dvn4@cdc.gov (M.  Patel).
1 These authors contributed equally.
ttp://dx.doi.org/10.1016/j.vaccine.2014.05.001
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-S antibody.
 Elsevier  Ltd. This is  an  open  access  article  under  the  CC  BY-NC-SA  license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).
for Disease Control and Prevention; DMSS, Defense Medical Surveillance System;
nzyme-linked immunosorbent assay; GMC, geometric mean concentration; GMT,
gococcal conjugate vaccine; MenACYWD, quadrivalent meningococcal conjugate
, quadrivalent meningococcal polysaccharide vaccine; NHRC, Naval Health Research
ad, MS C-25, Atlanta, GA 30333, USA. Tel.: +1 404 639 2422; fax: +1 404 639 9973.
A license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
3 ine 32
1
e
[
t
[
a
1
o
t
a
c
c
P
t
n
i
t
a
e
v
j
M
t
(
M
f
r
y
q
p
b
a
t
i
c
t
B
r
w
H
t
e
M
i
o
r
(
2
2
s
m
v
f
i
y
m
b806 M. Patel et al. / Vacc
. Introduction
In the United States, serogroups B, C and Y Neisseria meningitidis
ach account for approximately one-third of meningococcal cases
1]. From 1998 to 2007, serogroup C (MenC) disease resulted in
he highest case fatality ratio (14.6) among the three serogroups
1]. MenC often results in more severe sequelae in its survivors
nd has a predilection to cause outbreaks [2–4]. Sequence type (ST)
1/electrophoretic type (ET) 37 clonal complex was responsible for
utbreaks in U.S. army military recruits in the 1960s and continues
o cause outbreaks in the U.S. today [1,5]. Although disease rates for
ll serogroups are at a historic low, morbidity and mortality among
ases remains unchanged.
Prior to 2005, quadrivalent (A, C, Y, W)  meningococcal polysac-
haride vaccine, MPSV4 (Menomune®, Sanoﬁ Pasteur, Swiftwater,
A, USA), was used routinely in U.S. military recruits to reduce
he risk of disease during basic training. However, routine vacci-
ation of the general population was not recommended because of
ts limited duration of protection. In 2005, the Advisory Commit-
ee on Immunization Practices (ACIP) recommended vaccination of
dolescents and other persons at high risk for meningococcal dis-
ase with a newly licensed quadrivalent meningococcal conjugate
accine (MenACYW) [6]. Two quadrivalent meniningococcal con-
ugate vaccines are currently available for adolescents in the U.S.
enACWYD (Menactra®, diphtheria toxoid conjugate, Sanoﬁ Pas-
eur, Swiftwater, PA, USA) was licensed in 2005 and MenACWYCRM
MenveoTM, CRM-197 conjugate, Novartis Vaccines, Cambridge,
A,  USA) in 2010. The ACIP recommended use of either vaccine
or adolescents aged 11–18 years and other persons at increased
isk for meningococcal disease, including military recruits and ﬁrst
ear college students living in residential housing. Upon licensure,
uadrivalent meningococcal conjugate vaccines were expected to
rovide protection for at least 5–10 years. However, a limited num-
er of persistence studies conducted during clinical trials suggest
ntibody waning occurs faster than previously predicted [7,8].
To address increasing concern for limited duration of protec-
ion following vaccination with meningococcal conjugate vaccine,
n January 2011 the ACIP recommended a booster dose for adoles-
ents on or after their 16th birthday to provide optimal protection
hroughout the period of increased risk (16–21 years of age).
ooster doses continue to be recommended every 5 years for high
isk groups, such as those with certain immunologic disorders, as
ell as military personnel who continue to be at increased risk [9].
owever, data supporting the optimal interval for vaccination of
hese high risk groups are limited. The objective of this study is to
valuate antibody persistence to MenC following vaccination with
enACWYD in military personnel to inform US public health pol-
cy for quadrivalent meningococcal vaccines. Serologic responses
ver a 3 year period are compared to military recruits who were
outinely vaccinated with meningococcal polysaccharide vaccines
MPSV4) prior to licensure of conjugate vaccines.
. Materials and methods
.1. Study design and participants
We  conducted a retrospective cohort study among U.S. military
ervice personnel previously vaccinated with either quadrivalent
eningococcal conjugate (MenACWYD) or polysaccharide (MPSV4)
accine. Eligibility criteria included receipt of one dose of MPSV4
rom 2002 to 2004 or MenACWYD from 2006 to 2008, availabil-
ty of sera prior to vaccination, and at least one sample within 3
ears post-vaccination. Individuals with a history of ≥2 doses of
eningococcal vaccine were excluded. Subjects meeting the eligi-
ility criteria were selected from the U.S. Department of Defense’s (2014) 3805–3809
(DoD) Defense Medical Surveillance System (DMSS) electronic
database. DMSS integrates medical surveillance data for over ten
million individuals who  have served in the U.S. military since 1990
[10,11]. Sera that had been previously collected and subsequently
stored in the Department of Defense Serum Repository (DoDSR) as
part of public health surveillance were used to determine serolog-
ical responses to meningococcal vaccines.
To determine persistence of antibody responses to MenC fol-
lowing vaccination with MPSV4 or MenACWYD, 1200 subjects,
600 subjects per vaccination group, were randomly selected from
DMSS. Basic demographic information, including sex, age and race,
and meningococcal vaccination history were obtained from DMSS.
Pre-vaccination samples from all subjects were tested to determine
baseline levels. Two  hundred subjects, 100 subjects per vaccination
group, were evaluated during one of six post-vaccination time-
points: 5–7 months, 11–13 months, 17–19 months, 23–25 months,
29–31 months, or 35–37 months. Only one post-vaccination sample
per subject was tested.
The study was determined exempt from human subjects
research review by the Human Subjects Ofﬁces at the Naval Health
Research Center (NHRC) and Centers for Disease Control and Pre-
vention (CDC).
2.2. Serological responses
Serum bactericidal antibody titers to MenC were measured by a
validated rabbit complement serum bactericidal assay (rSBA) using
the target strain C11 [12,13]. Viability counts were determined with
an automated colony counter (Synbiosis Protocol, United King-
dom). A titer of 1.33 was  assigned to sera with no activity in the
initial serum dilution of 1:4. Continuous titers were interpolated
from 3-fold serum dilutions. Each sample was assigned a continu-
ous titer resulting in ≥50% killing compared to control wells. The
proportion of subjects with rSBA titers at or above the putative pro-
tective threshold of 8 was  calculated [14,15]. A more conservative
cutoff of 128 was also used to assess decay of immune responses
over time. Serum IgG anticapsular antibody concentrations were
determined using a standardized enzyme-linked immunosorbent
assay (ELISA) [16]. The concentration of speciﬁc IgG antibodies in
human sera was  calculated relative to a human standard refer-
ence serum pool, CDC 1992 [17]. Antibody concentrations below
the lower limit of quantitation (LLQ) of 0.001 g/mL were assigned
the LLQ. Data were captured with Gen5TM (BioTek) and analyzed
using ELISA for Windows (CDC, Atlanta, GA). The percent of subjects
with IgG antibody concentrations at or above 2 g/mL was deter-
mined [18,19]. Testing was  performed blinded to vaccine type and
time-point.
2.3. Statistical analysis
Sample size calculations with a two-sided alpha of 0.05 and
80% power were based on previous adult immunogenicity studies
of meningococcal conjugate and polysaccharide vaccines to deter-
mine the proportion of subjects with a threshold of ≥8 for rSBA
titers and ≥2 g/mL for IgG responses [8,20]. Statistical analysis
was performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Geometric mean titers (GMT) for rSBA and geometric mean con-
centrations (GMC) for ELISA were calculated for each vaccine group
per time-point. Because the log-transformed data were not nor-
mally distributed, continuous variables were compared using the
Wilcoxon rank sum test at each time point. A Chi-square test was
used to compare categorical variables, including the proportions
of subjects with rSBA titers ≥8 and ≥128, as well as the increase in
4-fold response compared to baseline for each time-point. Compar-
isons with a two-sided P value ≤0.05 were considered statistically
signiﬁcant. P-values for multiple tests across the seven time points
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Fig. 1. Box plots of (A) serum bactericidal titers measured by rSBA and (B) antibody concentrations measured by ELISA to MenC by months post-vaccination in MenACWYD
(gray bars) or MPSV4 (white bars) vaccine recipients. The box is deﬁned by the 25th and 75th percentiles of the distribution; the horizontal line within the box represents
t al line
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fhe  median or 50th percentile and the star (asterisk (*)) signiﬁes the mean. Vertic
istance (75th–25th percentiles) and the diamonds (♦) and boxes () correspond to
igniﬁcance (P < 0.05) between vaccine groups for that time-point.
ere adjusted for multiple comparisons by multiplying tested P-
alues by 7 and comparing them to 0.05 in a test for signiﬁcance.
. Results
Among the 1200 subjects evaluated, 83% were male and 68%
ere white. The mean age at the time of vaccination was  20.5
ears (range, 17–37) for MenACWYD and 20.0 years for MPSV4
range, 17–34). There were no signiﬁcant differences in sex and race
etween vaccine groups. Serum bactericidal activity and antibody
oncentrations to MenC were measured for all subjects prior to vac-
ination. Post-vaccination rSBA titers and antibody concentrations
ere analyzed in 1192 and 1190 subjects, respectively. Reasons
or exclusion included insufﬁcient volume for testing and failure tos extend to the most extreme observation that is less than 1.5× the interquartile
rate and severe outlying assay values, respectively. Cross bars (†) denote statistical
pass rSBA acceptance criteria for a reportable titer. The number of
serum samples excluded was similar between vaccine groups.
3.1. MenC serologic responses
Baseline rSBA GMT  was <8 for both vaccine groups (Fig. 1a). Five
to 7 months after vaccination, rSBA GMT  increased to 703 and 1557
in MenACWYD and MPSV4 groups, respectively. GMT  decreased by
>93% for both groups by 3 years post-vaccination (GMT 43 and
85 for MenACWYD and MPSV4 groups, respectively). There were
no signiﬁcant differences in GMT  between vaccine groups except
at 5–7 months post-vaccination (adjusted P < 0.05). GMC  were
<0.20 g/mL for both vaccine groups prior to vaccination (Fig. 1b).
Anti-MenC GMC  increased to 1.07 g/mL in the MenACWYD group
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Table 1
Proportion of subjects with a serum bactericidal titer ≥8 and ≥128 to meningococcal serogroup C and a 4-fold rise compared to baseline by time since vaccination with
MenACWYD or MPSV4.
Months after vaccination Number of subjects Percent with rSBA titer ≥8 Percent with rSBA titer ≥128 Percent with ≥4-fold rise compared to baseline
MenACWYD MPSV4 MenACWYD MPSV4 MenACWYD MPSV4 MenACWYD MPSV4
Pre 600 600 21 23 18 19 – –
5–7  99 99 87 87 80 85 77 79
11–13 99 99 73 80 65 74 65 72
17–19  99 100 72 83 64 78 55 71
23–25  100 99 69 68 51 61 64 51
29–31  99 98 66 59 53 52 57 53
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P35–37  100 100 54 62 
nd 6.00 g/mL in the MPSV4 group 5–7 months after vaccination.
y 3 years post-vaccination, GMC  decreased by 38% (0.66 g/mL)
or MenACWYD and 51% (2.95 g/mL) for MPSV4. GMC  were signif-
cantly different between vaccine groups for all time-points, with
he conjugate vaccine resulting in lower IgG antibody concentra-
ions than the polysaccharide vaccine (adjusted P < 0.0035).
.2. Proportion of subjects above a given threshold for Men  C
The percentages of subjects achieving a serum bactericidal titer
f ≥8 and ≥128 against MenC and a 4-fold rise compared to base-
ine are shown in Table 1. The proportion of subjects in both
accine groups with titers ≥8 and ≥128 at 3 years compared to
–7 months post-vaccination decreased by 29–38% and 35–43%,
espectively. There were no signiﬁcant differences between vac-
ine groups in the proportion of subjects with a titer of ≥8, ≥128,
r 4-fold increase from baseline at any time-point. The proportion
f subjects with MenC antibody concentrations ≥2.0 g/mL was
igniﬁcantly lower in the MenACWYD group at all post-vaccination
ime-points (Table 2).
. Discussion
This large-scale observational study of antibody persistence to
enC in U.S. military personnel demonstrates waning of immunity
ithin 3 years following vaccination with either MenACWYD or
PSV4. No signiﬁcant differences between the two vaccine groups
ere observed in the percentage of subjects at or above an rSBA
iter of 8, the putative protective level for MenC. Lower antibody
oncentrations among MenACWYD recipients may  be explained by
he quantity of antigen in each vaccine as MenACWYD contains 1/10
he serogroup C antigen of MPSV4. Despite lower antibody concen-
rations, functional activity (as measured by rSBA) was  comparable
etween vaccine groups, suggesting other immunologic responses
licited by conjugate vaccines likely contribute to overall protec-
ion. Conjugate vaccines are T-dependent and therefore induce
mmunologic memory and more rapid anamnestic responses
fter repeated doses, with antibody level typically several folds
reater than after initial vaccination. This boost response has been
able 2
roportion of subjects with antibody concentration ≥2 g/mL to meningococcal serogrou
Months after vaccination Number of subjects 
MenACWYD
Pre 600 
5–7a 98 
11–13a 99 
17–19a 99 
23–25a 100 
29–31a 99 
35–37a 100 
a P < 0.05, level of signiﬁcance.46 55 45 55
demonstrated after a repeat dose of MenACWYCRM 5 years after
primary vaccination [21]. Additionally, avidity maturation follow-
ing initial vaccination elicits highly speciﬁc antibodies with greater
bactericidal activity, and could thus explain the similarity in rSBA
response despite signiﬁcantly different antibody concentrations
between vaccine groups.
The importance of maintaining circulating antibodies to prevent
MenC disease has been reported in monovalent MenC conjugate
vaccine post-licensure studies in the United Kingdom [22,23].
Previously vaccinated subjects that developed MenC disease
demonstrated antibody levels and bactericidal activity comparable
to unvaccinated patients, despite evidence of immunologic mem-
ory [22]. Anamnestic responses can take up to 5 days to develop
and thus may  not be sufﬁciently rapid enough to prevent disease
[23].
Several U.S. studies have evaluated MenC antibody persistence
greater than 1 year following vaccination with quadrivalent conju-
gate vaccines in adolescents [7,8,21]. These studies were conducted
as extension studies within clinical trials, evaluated antibody per-
sistence in <500 subjects per study, and provided duration of
antibody response for only one time-point post-vaccination. Sero-
logic responses varied between studies and could be attributed to
differences in study population, type of protein conjugate used in
the vaccines, and assay methods and reagents (e.g., complement
source). Despite these differences, these studies demonstrated
waning of immunity to MenC of 60–72%, 35–80%, and 56% at 2, 3
and 5 years after vaccination, respectively. Additionally, one of the
studies suggested early evidence of waning at 2 years following vac-
cination MenACWYD and MenACWYCRM, regardless of brand type
[7]. Evaluation of immune responses during the ﬁrst month follow-
ing vaccination was  not conducted in our study; however, we were
able to demonstrate an antibody decay of over 93% in anti-MenC
serum bactericidal activity and over 38% in antibody concentrations
during multiple sampling periods between 6 months and 3 years
following vaccination with MenACWYD.Preliminary estimates from a quadrivalent meningococcal con-
jugate vaccine effectiveness (VE) study conducted in over 60%
of the US population demonstrates a decrease in VE from 82%
(CI = 54%–93%) for adolescents vaccinated <1 year earlier to 59%
p C by time since vaccination with MenACWYD or MPSV4.
Percent with anti-MenC IgG ≥2 g/mL
MPSV4 MenACWYD MPSV4
600 10 7
99 39 75
99 34 67
100 22 70
99 23 59
98 22 62
100 37 67
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CI = 5%–83%) for those vaccinated 3 to <6 years earlier [24].
hese data correlate well with our study in which almost half of
enACWYD recipients did not demonstrate putative protective
iters 3 years following a single dose.
This study supports the recent ACIP recommendation for a
ooster dose of meningococcal conjugate vaccine for adolescents
o maintain protection through late adolescence. Decay in antibody
esponses following a single dose of MenACWYD should be used
o inform policy recommendations regarding repeat vaccination
mong military personnel at increased risk. As the routine adoles-
ent booster dose is implemented, continued vaccine effectiveness
tudies, disease surveillance, and antibody persistence studies will
e important to evaluate the impact of the booster dose on duration
f protection.
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